DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: May 17, 2011

Department of Defense
Defense Health Program (DHP)
Fiscal Year 2012 Military Infectious Diseases Funding Opportunity

The DHP has assigned funds to support clinical trials focused on combat related infectious diseases. Solicitation of relevant Clinical Trial applications will be administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP). This pre-announcement should not be construed as an obligation by the government. The FY12 DMRDP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on Grants.gov in May 2011. Release of the official solicitation is pending. Additional funding mechanisms may be released at a later date.

Award Mechanism Eligibility Key Mechanism Elements Funding
Military Infectious Diseases - Clinical Trial Award Independent investigators at all academic levels (or equivalent)
  • Supports From proof of concept (i.e., first in human) trials through Phase II clinical trials, as well as Class I, II or III device trials
  • Proposed projects should demonstrate safety and efficacy of novel therapies in human patients
  • Preliminary data are required
  • Clinical trials are expected to be initiated within 12 months of the award date
  • Applications with collaborations partnering extramural academic industry and non-DOD federal investigators with intramural investigators, especially PIs at military treatment facilities (MTFs), are highly encouraged.
  • Applications focused on wound infection prevention and management as well as antimicrobial countermeasures are sought across one or more of the following focus areas:
    1. Therapeutic clinical trials-preventative or directive
    2. Clinical trials for new indications of FDA-approved drugs
    3. Therapeutic clinical trials
    4. Rapid detection of pathogens and/or microbial drug resistance markers
    5. Rapid detection of biomarkers
  • Maximum funding of $2.5 Million (M) for total costs
  • The maximum period of performance is 3 years
  • Anticipate approximately 4 awards

Information in this pre-announcement is being provided to allow investigators time to plan and develop applications. The government reserves the right to make changes to the award mechanism offered and the mechanism elements if necessary. All applications must conform to the final program announcement and application instructions that will be available for electronic downloading from the Grants.gov website in May 2011. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CDFA number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (https://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government's single-entry portal, Grants.gov.

Requests for email notification of the release of Program Announcements may be sent to help@cdmrp.org. For more information about CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact: